908 Devices Inc. (NASDAQ:MASS) Shares Sold by Nuveen Asset Management LLC

Nuveen Asset Management LLC lowered its stake in 908 Devices Inc. (NASDAQ:MASS - Free Report) by 47.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 106,951 shares of the company's stock after selling 97,420 shares during the period. Nuveen Asset Management LLC owned approximately 0.31% of 908 Devices worth $235,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Geode Capital Management LLC grew its stake in shares of 908 Devices by 2.4% during the fourth quarter. Geode Capital Management LLC now owns 581,300 shares of the company's stock valued at $1,279,000 after buying an additional 13,512 shares during the last quarter. Northern Trust Corp grew its stake in shares of 908 Devices by 7.5% during the fourth quarter. Northern Trust Corp now owns 200,764 shares of the company's stock valued at $442,000 after buying an additional 14,087 shares during the last quarter. Needham Investment Management LLC grew its stake in shares of 908 Devices by 100.0% during the fourth quarter. Needham Investment Management LLC now owns 200,000 shares of the company's stock valued at $440,000 after buying an additional 100,000 shares during the last quarter. Prescott Group Capital Management L.L.C. bought a new position in shares of 908 Devices during the fourth quarter valued at approximately $330,000. Finally, Jane Street Group LLC grew its stake in shares of 908 Devices by 118.9% during the fourth quarter. Jane Street Group LLC now owns 113,890 shares of the company's stock valued at $251,000 after buying an additional 61,851 shares during the last quarter. Hedge funds and other institutional investors own 88.06% of the company's stock.

908 Devices Trading Up 3.9%

Shares of NASDAQ MASS traded up $0.26 during trading hours on Friday, reaching $6.94. The stock had a trading volume of 451,064 shares, compared to its average volume of 1,017,142. The firm has a market cap of $248.88 million, a price-to-earnings ratio of -3.92 and a beta of 0.29. The business's fifty day moving average price is $5.03 and its two-hundred day moving average price is $3.54. 908 Devices Inc. has a 52-week low of $1.81 and a 52-week high of $7.32.

908 Devices (NASDAQ:MASS - Get Free Report) last announced its quarterly earnings results on Tuesday, May 13th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.27) by $0.05. The firm had revenue of $11.78 million during the quarter, compared to analyst estimates of $11.90 million. 908 Devices had a negative return on equity of 24.60% and a negative net margin of 109.11%. Equities research analysts anticipate that 908 Devices Inc. will post -1.99 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a "sell (e+)" rating on shares of 908 Devices in a research note on Saturday, May 24th. Two research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $5.33.

Insider Activity at 908 Devices

In other 908 Devices news, CFO Joseph H. Iv Griffith sold 6,940 shares of the company's stock in a transaction on Wednesday, June 4th. The stock was sold at an average price of $7.08, for a total transaction of $49,135.20. Following the completion of the sale, the chief financial officer now owns 102,930 shares in the company, valued at $728,744.40. This represents a 6.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Mark Spoto bought 10,000 shares of the stock in a transaction on Wednesday, May 14th. The shares were bought at an average price of $4.29 per share, with a total value of $42,900.00. Following the acquisition, the director now owns 62,971 shares of the company's stock, valued at $270,145.59. This trade represents a 18.88% increase in their ownership of the stock. The disclosure for this purchase can be found here. 23.70% of the stock is owned by company insiders.

908 Devices Company Profile

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.